Search

Your search keyword '"Ohama, A."' showing total 4,880 results
Start Over Author "Ohama, A."
4,880 results on '"Ohama, A."'

1. MARPF: Multi-Agent and Multi-Rack Path Finding

Author

Makino, Hiroya, Ohama, Yoshihiro, and Ito, Seigo

Subjects
Computer Science - Multiagent Systems
Abstract

In environments where many automated guided vehicles (AGVs) operate, planning efficient, collision-free paths is essential. Related research has mainly focused on environments with pre-defined passages, resulting in space inefficiency. We attempt to relax this assumption. In this study, we define multi-agent and multi-rack path finding (MARPF) as the problem of planning paths for AGVs to convey target racks to their designated locations in environments without passages. In such environments, an AGV without a rack can pass under racks, whereas one with a rack cannot pass under racks to avoid collisions. MARPF entails conveying the target racks without collisions, while the obstacle racks are relocated to prevent any interference with the target racks. We formulated MARPF as an integer linear programming problem in a network flow. To distinguish situations in which an AGV is or is not loading a rack, the proposed method introduces two virtual layers into the network. We optimized the AGVs' movements to move obstacle racks and convey the target racks. The formulation and applicability of the algorithm were validated through numerical experiments. The results indicated that the proposed algorithm addressed issues in environments with dense racks., Comment: 7 pages, 10 figures, IROS 2024

Published
2024

2. A patient who underwent conversion surgery after atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein thrombosis and perihepatic lymph node metastases achieved a pathological complete response

Author

Okuno, Masayuki, Ohama, Hideko, Nakamura, Ikuo, Yoshida, Makoto, Shirai, Daisuke, Hirai, Takahito, Fuji, Hiroaki, Kurimoto, Ami, Okamoto, Tomohiro, Sueoka, Hideaki, Iida, Kenjiro, Tada, Masaharu, Kihara, Takako, Tanaka, Hironori, and Hirono, Seiko

Published
2024
Full Text
View/download PDF

3. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Rossari, Federico, Yoo, Changhoon, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Bergamo, Francesca, Amadeo, Elisabeth, Vitiello, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Iavarone, Massimo Alberto, Cabibbo, Giuseppe, Montes, Margarida, Foschi, Francesco Giuseppe, Vivaldi, Caterina, Soldà, Caterina, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Bruccoleri, Mariangela, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Hiraoka, Atsushi, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Foti, Silvia, Camera, Silvia, Piscaglia, Fabio, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

5. Latent Conservative Objective Models for Data-Driven Crystal Structure Prediction

Author

Qi, Han, Geng, Xinyang, Rando, Stefano, Ohama, Iku, Kumar, Aviral, and Levine, Sergey

Subjects
Computer Science - Machine Learning
Abstract

In computational chemistry, crystal structure prediction (CSP) is an optimization problem that involves discovering the lowest energy stable crystal structure for a given chemical formula. This problem is challenging as it requires discovering globally optimal designs with the lowest energies on complex manifolds. One approach to tackle this problem involves building simulators based on density functional theory (DFT) followed by running search in simulation, but these simulators are painfully slow. In this paper, we study present and study an alternate, data-driven approach to crystal structure prediction: instead of directly searching for the most stable structures in simulation, we train a surrogate model of the crystal formation energy from a database of existing crystal structures, and then optimize this model with respect to the parameters of the crystal structure. This surrogate model is trained to be conservative so as to prevent exploitation of its errors by the optimizer. To handle optimization in the non-Euclidean space of crystal structures, we first utilize a state-of-the-art graph diffusion auto-encoder (CD-VAE) to convert a crystal structure into a vector-based search space and then optimize a conservative surrogate model of the crystal energy, trained on top of this vector representation. We show that our approach, dubbed LCOMs (latent conservative objective models), performs comparably to the best current approaches in terms of success rate of structure prediction, while also drastically reducing computational cost.

Published
2023

6. Transmission of global clones of NDM-producing Enterobacterales and interspecies spread of IncX3 plasmid harbouring blaNDM-5 in Tokyo

Author

Sohei Harada, Kotaro Aoki, Yusuke Nomura, Yuki Ohama, Hideki Araoka, Brian Hayama, Takayuki Sakurai, Akihiro Ueda, Yoshikazu Ishii, and Takeya Tsutsumi

Subjects
Carbapenemase-producing enterobacterales, NDM-type carbapenemase, IncX3 plasmid, Nosocomial spread, Microbiology, QR1-502
Abstract

Objective: The aim of this study is to characterise the molecular characteristics of NDM-producing Enterobacterales, which have been on the increase in recent years in Japan, where IMP-producing bacteria are dominant among carbapenemase-producing Enterobacterales. Methods: We collected 21 strains of NDM-producing Enterobacterales detected between 2015 and 2022 at five hospitals in Tokyo and performed illumina whole genome sequencing. For the seven selected strains, nanopore long-read sequencing was also performed to characterise the plasmids harbouring blaNDM. Results: Fourteen strains were Escherichia coli and all carried blaNDM-5. Among these strains, eight and three were sequence type (ST) 410 and ST167, respectively, and both groups of strains were spread clonally in different hospitals. Two strains of Klebsiella pneumoniae ST147 carrying blaNDM-1 were detected in a hospital, and these strains had also spread clonally. The remainder included Enterobacter hormaechei, Klebsiella quasipneumoniae, Citrobacter amalonaticus, and Klebsiella michiganensis. Plasmid analysis revealed that an identical IncX3 plasmid harbouring blaNDM-5 was shared among four strains of different bacterial species (E. coli, C. amalonaticus, K. michiganensis, and E. hormaechei) detected at the same hospital. In addition, a Klebsiella quasipneumoniae strain detected at a different hospital also carried an IncX3 plasmid with a similar genetic structure. Conclusions: Nosocomial spread of multiple multidrug-resistant global clones and transmission of IncX3 plasmids harbouring blaNDM-5 among multiple species were detected as the major pathways of spread of NDM-producing Enterobacterales in Tokyo. Early detection of carriers and measures to prevent nosocomial spread are important to prevent further spread of NDM-producing organisms.

Published
2024
Full Text
View/download PDF

8. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

Author

Camera, Silvia, Rimini, Margherita, Rossari, Federico, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Yoo, Changhoon, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Bergamo, Francesca, Salani, Francesca, Marseglia, Mariarosaria, Amadeo, Elisabeth, Vitiello, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Iavarone, Massimo, Cabibbo, Giuseppe, Montes, Margarida, Foschi, Francesco Giuseppe, Vivaldi, Caterina, Lonardi, Sara, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Hiraoka, Atsushi, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Persano, Mara, Foti, Silvia, Piscaglia, Fabio, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

9. Detection of novel us neisseria meningitidis urethritis clade subtypes in japan

Author

Takahashi, Hideyuki, Morita, Masatomo, Yasuda, Mitsuru, Ohama, Yuki, Kobori, Yoshitomo, Kojima, Munekado, Shimuta, Ken, Akeda, Yukihiro, and Ohnishi, Makoto

Subjects
Nucleotide sequencing -- Health aspects, Meningitis -- Health aspects, Penicillin G -- Health aspects, Urethritis -- Health aspects, Genomics -- Health aspects, Sexually transmitted diseases -- Health aspects, DNA sequencing -- Health aspects, Genomes -- Health aspects, Disease transmission -- Health aspects, Health
Abstract

Neisseria meningitidis causes invasive meningococcal diseases (IMDs), such as meningitis and septicemia. N. meningitidis is classified into 12 defined serogroups; however, most IMDs are associated with the serogroups A, B, [...]

Published
2023
Full Text
View/download PDF

10. Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices

Author

Tada, Fujimasa, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Naganuma, Atsushi, Kosaka, Hisashi, Matono, Tomomitsu, Kuroda, Hidekatsu, Yata, Yutaka, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Yokohama, Keisuke, Nishikawa, Hiroki, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Iijima, Hiroko, Kaibori, Masaki, Hiasa, Yoichi, and Kumada, Takashi

Published
2023
Full Text
View/download PDF

11. Alterations in the fillet quality of myostatin-knockout red sea bream Pagrus major: Preliminary insights into nutritional, compositional, and textural properties

Author

Yu Murakami, Masashi Ando, Kenta Kishimoto, Mitsuki Ohama, Yuto Uemura, Reoto Tani, Atsushi Akazawa, Kentaro Matsumiya, Kenji Sato, and Masato Kinoshita

Subjects
Myostatin, Genome editing, Red sea bream, Fillet quality, Water-holding capacity, Texture, Science (General), Q1-390, Social sciences (General), H1-99
Abstract

Myostatin (MSTN) is a negative regulator of skeletal muscle growth and a popular target for enhancing the productivity of farmed fish. We previously developed an mstn-knockout breed of the aquaculture fish red sea bream (Pagrus major) using genome editing technology. However, little is known about the effects of mstn disruption on the fillet quality of red sea bream and other fish species. In this study, we used fillets of mstn-deficient red sea bream to evaluate their compositional and textural changes during refrigeration. Compared to the wild type, the mutant fillets exhibited an increase in moisture content and a decrease in drippings, indicating an enhanced water-holding capacity. Furthermore, the mutant fillets showed increased water retention and marginally lower collagen content, resulting in lower breaking force, an index of texture. In conclusion, we demonstrated that mstn disruption alters the compositional and textural properties of red sea bream fillets.

Published
2024
Full Text
View/download PDF

12. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma

Author

Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Takeshi Hatanaka, Joji Tani, Koichi Takaguchi, Masanori Atsukawa, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Kazuto Tajiri, Toru Ishikawa, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Chikara Ogawa, Satoru Kakizaki, Noritomo Shimada, Atsushi Naganuma, Kazuhito Kawata, Hisashi Kosaka, Hidekatsu Kuroda, Tomomitsu Matono, Yutaka Yata, Hironori Ochi, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Keisuke Yokohama, Hiroki Nishikawa, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Takashi Kumada, and Representing the Real‐life Practice Experts for HCC Study Group with Hepatocellular Carcinoma experts from 48 clinics in Japan (RELPEC/HCC 48 Group)

Subjects
atezolizumab plus bevacizumab, CRAFITY score, hepatocellular carcinoma, IMABALI score, IMABALI‐De score, modified albumin‐bilirubin grade, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Aims The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods A total of 719 patients (males 577, median age 74 years) treated with Atez/Bev between September 2020 and January 2023 were enrolled. Factors related to overall survival (OS) were extracted and a prognostic scoring system based on hazard ratio (HR) was created. OS and progression‐free survival (PFS) were retrospectively examined, and the prognostic ability of the newly developed system was compared to CRAFITY score using concordance index (c‐index) and Akaike information criterion (AIC) results. Results Cox‐hazards multivariate analysis showed BCLC classification C/D (HR 1.4; 1 point), AFP ≥100 ng/mL (HR 1.4; 1 point), mALBI 2a (HR 1.7; 1 point), mALBI 2b/3 (HR 2.8; 2 points), and DCP ≥100 mAU/mL (HR 1.6; 1 point) as significant factors. The assigned points were added and used to develop the IMmunotherapy with AFP, BCLC staging, mALBI, and DCP evaluation (IMABALI‐De) scoring system. For IMABALI‐De scores of 0, 1, 2, 3, 4, and 5, OS was not applicable (NA), NA, 26.11, 18.79, 14.07, and 8.32 months, respectively (p

Published
2024
Full Text
View/download PDF

13. Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study

Author

Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Caterina Soldà, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Mara Persano, Silvia Foti, Silvia Camera, Bernardo Stefanini, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini, and Margherita Rimini

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Introduction The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post-hoc analyses of IMbrave-150 and metanalyses of clinical trials of PD-1/PD-L1 blockers. As a results, it is not clear whether the first-line systemic treatment atezolizumab plus bevacizumab is equally effective in viral and non-viral patients. Methods We retrospectively analyzed 885 HCC patients treated with first-line A + B from multiple centers from Eastern and Western countries, 53.9% having viral and 46.1% non-viral etiology. Baseline clinical and laboratory characteristics were analyzed with uni- and multi-variate models to explore potential differences on overall survival (OS), time to progression (TTP), disease control rates based on etiology and to identify putative prognostic factors in etiology subgroups. Treatment toxicities and access to second-line treatments and outcomes were also reported and compared between etiologies. Results Overall, no statistically significant differences were found in OS (mOS: viral 15.9 months; non-viral 16.3 months), TTP (mTTP: viral 8.3 months; non-viral 7.2 months), and disease control rates (DCR: viral 78.1%; non-viral 80.8%) based on etiology. Prognostic factors of survival and progression were mainly shared between viral and non-viral etiologies, including alpha-fetoprotein, aspartate transaminase, neutrophil-to-lymphocyte ratio (NLR) and ALBI score. Exploratory analyses highlighted a possible stronger association of immunological factors, i.e. NLR and eosinophil count, to treatment outcomes in viral patients. The toxicity profile, the access to and type of second-line treatments and their outcome in terms of OS almost overlap in the two etiology subgroups. Conclusion Atezolizumab plus bevacizumab efficacy does not vary according to underlying etiology of HCC in a multicenter, real-world population, matching recent post-hoc findings from the IMbrave-150 trial. Preliminary analyses suggest that some prognostic factors differ between viral and non-viral patients, potentially due to biological and immunological differences. Prospective and comparative trials stratifying by etiology are warranted to validate these findings and guide clinical practice.

Published
2024
Full Text
View/download PDF

15. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Salani, Francesca, Lonardi, Sara, Piscaglia, Fabio, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Schirripa, Marta, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

16. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Rimassa, Lorenza, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Kawaguchi, Takumi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Piscaglia, Fabio, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Scartozzi, Mario, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Cammarota, Antonella, Burgio, Valentina, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

17. Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed‐effects regression model approach

Author

Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Keisuke Yokohama, Hiroki Nishikawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Atsushi Naganuma, Yutaka Yata, Hideko Ohama, Hidekatsu Kuroda, Kazunari Tanaka, Takaaki Tanaka, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, and the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

Subjects
ALBI score, atezolizumab plus bevacizumab, lenvatinib, liver function, mixed‐effects regression model, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Aim This retrospective study compared the impact of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) on the liver function in patients with hepatocellular carcinoma. Methods We included 526 patients who received Atez/Bev and 731 who received LEN March 2018 and July 2022 in this study. We conducted a 1:1 propensity‐score‐matched analysis and identified 324 patients in each group for inclusion in the present analysis. Nonlinear mixed‐effects regression models were employed, allowing for the evaluation and inclusion of cases where treatment was interrupted due to disease progression, adverse events, or loss to follow‐up. These models were used to compare the ALBI score between the Atez/Bev and LEN groups. Results Following propensity score matching, the mean ALBI scores in the Atez/Bev and LEN groups were −2.41 ± 0.40 and −2.44 ± 0.42 at baseline, and −2.17 ± 0.56 and −2.19 ± 0.58 at 12 weeks, respectively. Although the ALBI score significantly worsened during treatment in both groups (p

Published
2023
Full Text
View/download PDF

18. Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019

Author

Barbara Andraka-Christou, Olivia Golan, Rachel Totaram, Maggie Ohama, Brendan Saloner, Adam J. Gordon, and Bradley D. Stein

Subjects
Buprenorphine, methadone, naltrexone, opioid use disorder, medication-assisted treatment, prior authorization, Medicine
Abstract

AbstractResearch objective Medications for opioid use disorder (MOUDs) – including methadone, buprenorphine, and naltrexone – are the most effective treatments for opioid use disorder (OUD). Historically, insurers have required prior authorization for MOUD, but prior authorization is often reported as a key barrier to MOUD prescribing. Some states have passed laws prohibiting MOUD prior authorization requirements. We sought to identify the frequency of MOUD prior authorization prohibitions in state laws and to categorize types of prohibitions.Methods We searched for regulations and statutes present in all U.S. states and Washington DC between 2005 and 2019 using MOUD-related terms in Westlaw legal software. In qualitative software, we coded laws discussing MOUD prior authorization using template analysis – a mixed deductive/inductive approach. Finally, we used coded laws to identify frequencies of states with prior authorization prohibitions, including changes over time.Results No states had laws prohibiting MOUD prior authorization between 2005 and 2015, with the first prohibition appearing in 2016. By 2019, fifteen states had MOUD prior authorization prohibitions. States varied significantly in their approach to prohibiting MOUD prior authorization. In 2019, it was more common for states to have MOUD prior authorization prohibitions applying to all insurers (n = 10 states) than to only Medicaid (n = 7 states) or only non-Medicaid insurers (n = 1 state). In 2019, general prior authorization prohibitions (n = 10 states) were more common than prohibitions only applicable to medications on the formulary, prohibitions only applicable to medications on the preferred drug list, prohibitions only applicable during the first 5 days of treatment, and prohibitions only applicable during the first 30 days of treatment.Conclusions The number of states with an MOUD prior authorization law prohibition increased in recent years. Such laws could help expand access to life-saving OUD treatments by making it easier for clinicians to prescribe MOUD.KEY MESSAGESNo states had MOUD prior authorization prohibitions between 2005 and 2015 in state statutes or regulations, and only one state had such a prohibition in 2016.By 2019, fifteen states had an MOUD prior authorization prohibition law.States varied significantly in their approach to prohibiting MOUD prior authorization, including with respect to the insurer type, duration of the prohibition, and applicable medication.

Published
2023
Full Text
View/download PDF

19. Detection of Novel US Neisseria meningitidis Urethritis Clade Subtypes in Japan

Author

Hideyuki Takahashi, Masatomo Morita, Mitsuru Yasuda, Yuki Ohama, Yoshitomo Kobori, Munekado Kojima, Ken Shimuta, Yukihiro Akeda, and Makoto Ohnishi

Subjects
Neisseria meningitidis, meningococci, serogroup, invasive meningococcal diseases, urethritis, urethritis clade, Medicine, Infectious and parasitic diseases, RC109-216
Abstract

Neisseria meningitidis causes invasive meningococcal diseases and has also been identified as a causative agent of sexually transmitted infections, including urethritis. Unencapsulated sequence type 11 meningococci containing the gonococcal aniA-norB locus and belonging to the United States N. meningitidis urethritis clade (US_NmUC) are causative agents of urethral infections in the United States, predominantly among men who have sex with men. We identified 2 subtypes of unencapsulated sequence type 11 meningococci in Japan that were phylogenetically close to US_NmUC, designated as the Japan N. meningitidis urethritis clade (J_NmUC). The subtypes were characterized by PCR, serologic testing, and whole-genome sequencing. Our study suggests that an ancestor of US_NmUC and J_NmUS urethritis-associated meningococci is disseminated worldwide. Global monitoring of urethritis-associated N. meningitidis isolates should be performed to further characterize microbiologic and epidemiologic characteristics of urethritis clade meningococci.

Published
2023
Full Text
View/download PDF

20. Contrastive Neural Processes for Self-Supervised Learning

Author

Kallidromitis, Konstantinos, Gudovskiy, Denis, Kozuka, Kazuki, Ohama, Iku, and Rigazio, Luca

Subjects
Computer Science - Machine Learning, Electrical Engineering and Systems Science - Signal Processing
Abstract

Recent contrastive methods show significant improvement in self-supervised learning in several domains. In particular, contrastive methods are most effective where data augmentation can be easily constructed e.g. in computer vision. However, they are less successful in domains without established data transformations such as time series data. In this paper, we propose a novel self-supervised learning framework that combines contrastive learning with neural processes. It relies on recent advances in neural processes to perform time series forecasting. This allows to generate augmented versions of data by employing a set of various sampling functions and, hence, avoid manually designed augmentations. We extend conventional neural processes and propose a new contrastive loss to learn times series representations in a self-supervised setup. Therefore, unlike previous self-supervised methods, our augmentation pipeline is task-agnostic, enabling our method to perform well across various applications. In particular, a ResNet with a linear classifier trained using our approach is able to outperform state-of-the-art techniques across industrial, medical and audio datasets improving accuracy over 10% in ECG periodic data. We further demonstrate that our self-supervised representations are more efficient in the latent space, improving multiple clustering indexes and that fine-tuning our method on 10% of labels achieves results competitive to fully-supervised learning., Comment: 16 pages, 6 figures, ACML 2021

Published
2021

23. Determination of the magnetic q vectors in the heavy fermion superconductor Ce3PtIn11

Author

Shioda, Naoki, Kumeda, Kazuki, Fukazawa, Hideto, Ohama, Tetsuo, Kohori, Yoh, Das, Debarchan, Blawat, Joanna, Kaczorowski, Dariusz, and Sugimoto, Koudai

Subjects
Condensed Matter - Strongly Correlated Electrons, Condensed Matter - Superconductivity
Abstract

An analysis with transferred hyperfine field has been performed on the spectra of the $^{115}$In nuclear quadrupole resonance experiments of heavy fermion superconductor Ce$_{3}$PtIn$_{11}$ exhibiting co-occurrence of two successive antiferromagnetic orderings ($T_{\rm N1}$ = 2.2 K and $T_{\rm N2}$ = 2.0 K) followed by superconducting transition ($T_{\rm c}$ = 0.32 K). The spectral changes at magnetic transition temperatures $T_{\rm N1}$ and $T_{\rm N2}$ indicate that the Ce(2) site has the dominant magnetic contribution, with a small magnetic moment, but not negligible, at the Ce(1) site. Our analysis using transferred hyperfine field which overcomes the previous simple dipolar model evinces that for $T_{\rm N2} < T < T_{\rm N1 } $, the propagation vectors at the Ce(1) and Ce(2) sublattices are q1 = q2 = (1/2, 1/2, 0 or 1/2), whereas for $T < T_{\rm N2 }$, the propagation vectors are q1 = (1/2,~1/2, 1/6 or 1/3) and q2 = (1/2, 1/2, 1/2 or 0), respectively., Comment: 15 pages, 4figures

Published
2021
Full Text
View/download PDF

24. Massive star formation in the Carina nebula complex and Gum 31 -- II. a cloud-cloud collision in Gum 31

Author

Fujita, Shinji, Sano, Hidetoshi, Enokiya, Rei, Hayashi, Katsuhiro, Kohno, Mikito, Tsuge, Kisetsu, Tachihara, Kengo, Nishimura, Atsushi, Ohama, Akio, Yamane, Yumiko, Ohno, Takahiro, Yamada, Rin I., and Fukui, Yasuo

Subjects
Astrophysics - Astrophysics of Galaxies
Abstract

We present the results of analyses of the 12CO (J=1-0), 13CO (J=1-0), and 12CO (J=2-1) emission data toward Gum 31. Three molecular clouds separated in velocity were detected at -25, -20, and -10 km/s . The velocity structure of the molecular clouds in Gum 31 cannot be interpreted as expanding motion. Two of them, the -25 km/s cloud and the -20 km/s cloud, are likely associated with Gum 31, because their 12CO (J=2-1)/12CO (J=1-0) intensity ratios are high. We found that these two clouds show the observational signatures of cloud-cloud collisions (CCCs): a complementary spatial distribution and a V-shaped structure (bridge features) in the position-velocity diagram. In addition, their morphology and velocity structures are very similar to the numerical simulations conducted by the previous studies. We propose a scenario that the -25 km/s cloud and the -20 km/s cloud were collided and triggered the formation of the massive star system HD 92206 in Gum 31. This scenario can explain the offset of the stars from the center and the morphology of Gum 31 simultaneously. The timescale of the collision was estimated to be ~1 Myr by using the ratio between the path length of the collision and the assumed velocity separation. This is consistent with that of the CCCs in Carina Nebula Complex in our previous study., Comment: Accepted for publication in PASJ

Published
2021
Full Text
View/download PDF

27. Long-term survival of patients receiving home hemodialysis with self-punctured arteriovenous access.

Author

Koji Tomori, Tsutomu Inoue, Masao Sugiyama, Naoto Ohashi, Hiroshi Murasugi, Kazuya Ohama, Hiroaki Amano, Yusuke Watanabe, and Hirokazu Okada

Subjects
Medicine, Science
Abstract

ObjectiveTo determine the long-term survival of patients receiving home hemodialysis (HHD) through self-punctured arteriovenous access.MethodsWe conducted an observational study of all patients receiving HHD at our facility between 2001 and 2020. The primary outcome was treatment survival, and it was defined as the duration from HHD initiation to the first event of death or technique failure. The secondary outcomes were the cumulative incidence of technique failure and mortality. Cox proportional hazard models were used to identify the predictive factors for treatment survival.ResultsA total of 77 patients (mean age, 50.7 years; 84.4% male; 23.4% with diabetes) were included. The median dialysis duration was 18 hours per week, and all patients self-punctured their arteriovenous fistula. During a median follow-up of 116 months, 30 treatment failures (11 deaths and 19 technique failures) were observed. The treatment survival was 100% at 1 year, 83.5% at 5 years, 67.2% at 10 years, and 34.6% at 15 years. Age (adjusted hazard ratio [aHR], 1.07) and diabetes (aHR, 2.45) were significantly associated with treatment survival. Cardiovascular disease was the leading cause of death, and vascular access-related issues were the primary causes of technique failure, which occurred predominantly after 100 months from HHD initiation.ConclusionThis study showed a favorable long-term prognosis of patients receiving HHD. HHD can be a sustainable form of long-term kidney replacement therapy. However, access-related technique failures occur more frequently in patients receiving it over the long term. Therefore, careful management of vascular access is crucial to enhance technique survival.

Published
2024
Full Text
View/download PDF

28. Simple method for predicting muscle volume loss using geriatric nutritional risk index in hepatocellular carcinoma patients

Author

Atsushi Hiraoka, Hideko Ohama, Fujimasa Tada, Yoshiko Fukunishi, Emi Yanagihara, Kanako Kato, Masaya Kato, Hironobu Saneto, Hirofumi Izumoto, Hidetaro Ueki, Takeaki Yoshino, Shogo Kitahata, Tomoe Kawamura, Taira Kuroda, Yoshifumi Suga, Hideki Miyata, Masashi Hirooka, Masanori Abe, Bunzo Matsuura, Tomoyuki Ninomiya, and Yoichi Hiasa

Subjects
Diseases of the musculoskeletal system, RC925-935, Human anatomy, QM1-695
Published
2023
Full Text
View/download PDF

29. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer

Author

Umemoto, Kumiko, Sunakawa, Yu, Ueno, Makoto, Furukawa, Masayuki, Mizuno, Nobumasa, Sudo, Kentaro, Kawamoto, Yasuyuki, Kajiwara, Takeshi, Ohtsubo, Koushiro, Okano, Naohiro, Matsuhashi, Nobuhisa, Itoh, Shinji, Matsumoto, Toshihiko, Shimizu, Satoshi, Otsuru, Toru, Hasegawa, Hiroko, Okuyama, Hiroyuki, Ohama, Hideko, Moriwaki, Toshikazu, Ohta, Takashi, Odegaard, Justin I., Nakamura, Yoshiaki, Bando, Hideaki, Yoshino, Takayuki, Ikeda, Masafumi, and Morizane, Chigusa

Published
2023
Full Text
View/download PDF

31. Development of the new multi-beam receiver and telescope control system for NASCO

Author

Nishimura, Atsushi, Ohama, Akio, Kimura, Kimihiro, Tsutsumi, Daichi, Matsue, Yudai, Yamada, Rin, Sakamoto, Mariko, Matsunaga, Kenta, Hasegawa, Yutaka, Minami, Taisei, Matsumoto, Takeru, Shiotani, Kazuki, Okuda, So, Fujishiro, Kakeru, Sakasai, Keisuke, Suzuki, Masahiro, Saeki, Shun, Satani, Kouki, Urushihara, Kousuke, Kato, Chiharu, Kondo, Takashi, Okawa, Kazuki, Kurita, Daiki, Inaba, Tetsuta, Maruyama, Shohei, Koga, Masako, Noda, Kenya, Kohno, Mikito, Iwamura, Hiroaki, Hyoto, Yuki, Hori, Yuichi, Nishikawa, Kaoru, Nishioka, Takeru, Pang, Thoqin, Sano, Hidetoshi, Enokiya, Rei, Yoshiike, Satoshi, Fujita, Shinji, Hayashi, Katsuhiro, Torii, Kazufumi, Hayakawa, Takahiro, Taniguchi, Akio, Tsuge, Kisetsu, Yamane, Yumiko, Hattori, Yusuke, Ohno, Takahiro, Ueda, Shota, Masui, Sho, Yamasaki, Yasumasa, Kondo, Hiroshi, Suzuki, Kazuji, Kobayashi, Kazuhiro, Fujii, Yasunori, Fujii, Yumi, Minamidani, Tetsuhiro, Okuda, Takeshi, Yamamoto, Hiroaki, Tachihara, Kengo, Onishi, Toshikazu, Mizuno, Akira, Ogawa, Hideo, and Fukui, Yasuo

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

We report the current status of the NASCO (NAnten2 Super CO survey as legacy) project which aims to provide all-sky CO data cube of southern hemisphere using the NANTEN2 4-m submillimeter telescope installed at the Atacama Desert through developing a new multi-beam receiver and a new telescope control system. The receiver consists of 5 beams. The four beams, located at the four corners of a square with the beam separation of 720$''$, are installed with a 100 GHz band SIS receiver having 2-polarization sideband-separation filter. The other beam, located at the optical axis, is installed with a 200 GHz band SIS receiver having 2-polarization sideband-separation filter. The cooled component is modularized for each beam, and cooled mirrors are used. The IF bandwidths are 8 and 4 GHz for 100 and 200 GHz bands, respectively. Using XFFTS spectrometers with a bandwidth of 2 GHz, the lines of $^{12}$CO, $^{13}$CO, and C$^{18}$O of $J$=1$-$0 or $J$=2$-$1 can be observed simultaneously for each beam. The control system is reconstructed on the ROS architecture, which is an open source framework for robot control, to enable a flexible observation mode and to handle a large amount of data. The framework is commonly used and maintained in a robotic field, and thereby reliability, flexibility, expandability, and efficiency in development are improved as compared with the system previously used. The receiver and control system are installed on the NANTEN2 telescope in December 2019, and its commissioning and science verification are on-going. We are planning to start science operation in early 2021., Comment: submitted to SPIE Astronomical Telescopes + Instrumentation (AS20), paper No. 11453-146

Published
2020

32. Formation of the Musca filament: Evidence for asymmetries in the accretion flow due to a cloud-cloud collision

Author

Bonne, L., Bontemps, S., Schneider, N., Clarke, S. D., Arzoumanian, D., Fukui, Y., Tachihara, K., Csengeri, T., Guesten, R., Ohama, A., Okamoto, R., Simon, R., Yahia, H., and Yamamoto, H.

Subjects
Astrophysics - Astrophysics of Galaxies
Abstract

Context. Dense molecular filaments are ubiquituous in the interstellar medium, yet their internal physical conditions and formation mechanism remain debated. Aims. We study the kinematics and physical conditions in the Musca filament and the Chamaeleon-Musca complex to constrain the physics of filament formation. Methods. We produced CO(2-1) isotopologue maps with the APEX telescope that cut through the Musca filament. We further study a NANTEN2 $^{12}$CO(1-0) map of the Musca cloud and the HI emission of the Chamaeleon-Musca complex. Results. The Musca cloud contains multiple velocity components. Radiative transfer modelling of the CO emission indicates that the Musca filament consists of a cold ($\sim$10 K), dense (n$_{H_2}\sim$10$^4$ cm$^{-3}$) crest, which is best described with a cylindrical geometry. Connected to the crest, a separate gas component at T$\sim$15 K and n$_{H_2}\sim$10$^3$ cm$^{-3}$ is found, the so-called strands. The filament crest has a transverse velocity gradient that is linked to the kinematics of the nearby ambient cloud. Studying the large scale kinematics, we find coherence of the asymmetric kinematics from the 50 pc HI cloud down to the Musca filament. We also report a strong [C$^{18}$O]/[$^{13}$CO] abundance drop by an order of magnitude from the filament crest to the strands over a distance $<$ 0.2 pc in a weak far-ultraviolet (FUV) field. Conclusions. The dense Musca filament crest is a long-lived (several crossing times), dynamic structure that can form stars in the near future because of continuous mass accretion. This mass accretion appears to be triggered by a HI cloud-cloud collision, which bends the magnetic field around dense filaments. This bending of the magnetic field is then responsible for the observed asymmetric accretion scenario of the Musca filament, which is, for instance, seen as a V-shape in the position-velocity (PV) diagram., Comment: 24 pages, 26 figures

Published
2020
Full Text
View/download PDF

34. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Piscaglia, Fabio, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Rimassa, Lorenza, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

36. Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab

Author

Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Shimada, Noritomo, Kawata, Kazuhito, Kosaka, Hisashi, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, and Kumada, Takashi

Published
2023
Full Text
View/download PDF

37. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Author

Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, and Yoichi Hiasa

Subjects
adverse event, atezolizumab plus bevacizumab, hepatocellular carcinoma, survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Aim To investigate the possible correlation between the development of adverse events (AEs) and prognosis in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/Bev). Methods A total of 286 patients with unresectable HCC treated with Atez/Bev as first‐line systematic therapy were included. Results Regarding treatment‐related AEs, decreased appetite of any grade, proteinuria of any grade, and fatigue of any grade were found with a frequency of ≥20%. Multivariate analysis adjusted for immune‐related liver injury, immune‐related endocrine dysfunction, proteinuria, fatigue, decreased appetite, hypertension, sex, age, Eastern Cooperative Oncology Group performance status, HCC etiology, HCC stage, Child–Pugh score, and α‐fetoprotein showed that hypertension of any grade (hazard ratio [HR], 0.527; 95% confidence interval [CI], 0.326–0.854; p = 0.009) and α‐fetoprotein ≥100 ng/ml (HR, 1.642; 95% CI, 1.111–2.427; p = 0.013) were independently associated with progression‐free survival. Multivariate analysis adjusted for the same AEs showed that fatigue (HR, 2.354; 95% CI, 1.299–4.510; p = 0.010) was independently associated with overall survival. Median progression‐free survival was 6.5 months (95% CI, 5.2–8.1) in patients without hypertension of any grade and 12.6 months (95% CI, 6.7–not available) in patients with hypertension of any grade (p = 0.035). The overall survival was significantly shorter in patients in whom treatment‐related fatigue of any grade was observed (p

Published
2023
Full Text
View/download PDF

38. Triggered high-mass star formation in the HII region W28A2: A cloud-cloud collision scenario

Author

Hayashi, Katsuhiro, Yoshiike, Satoshi, Enokiya, Rei, Fujita, Shinji, Yamada, Rin, Sano, Hidetoshi, Torii, Kazufumi, Kohno, Mikito, Nishimura, Atsushi, Ohama, Akio, Yamamoto, Hiroaki, Tachihara, Kengo, Wong, Graeme, Maxted, Nigel, Braiding, Catherine, Rowell, Gavin, Burton, Michael, and Fukui, Yasuo

Subjects
Astrophysics - Astrophysics of Galaxies
Abstract

We report on a study of the high-mass star formation in the the HII region W28A2 by investigating the molecular clouds extended over ~5-10 pc from the exciting stars using the 12CO and 13CO (J=1-0) and 12CO (J=2-1) data taken by the NANTEN2 and Mopra observations. These molecular clouds consist of three velocity components with the CO intensity peaks at V_LSR ~ -4 km s$^{-1}$, 9 km s$^{-1}$ and 16 km s$^{-1}$. The highest CO intensity is detected at V_LSR ~ 9 km s$^{-1}$, where the high-mass stars with the spectral types of O6.5-B0.5 are embedded. We found bridging features connecting these clouds toward the directions of the exciting sources. Comparisons of the gas distributions with the radio continuum emission and 8 um infrared emission show spatial coincidence/anti-coincidence, suggesting physical associations between the gas and the exciting sources. The 12CO J=2-1 to 1-0 intensity ratio shows a high value (> 0.8) toward the exciting sources for the -4 km s$^{-1}$ and +9 km s$^{-1}$ clouds, possibly due to heating by the high-mass stars, whereas the intensity ratio at the CO intensity peak (V_LSR ~ 9 km s$^{-1}$) lowers down to ~0.6, suggesting self absorption by the dense gas in the near side of the +9 km s$^{-1}$ cloud. We found partly complementary gas distributions between the -4 km s$^{-1}$ and +9 km s$^{-1}$ clouds, and the -4 km s$^{-1}$ and +16 km s$^{-1}$ clouds. The exciting sources are located toward the overlapping region in the -4 km s$^{-1}$ and +9 km s$^{-1}$ clouds. Similar gas properties are found in the Galactic massive star clusters, RCW 38 and NGC 6334, where an early stage of cloud collision to trigger the star formation is suggested. Based on these results, we discuss a possibility of the formation of high-mass stars in the W28A2 region triggered by the cloud-cloud collision., Comment: 26 pages, 16 figures, Accepted for publication in PASJ

Published
2020
Full Text
View/download PDF

39. Massive star formation in the Carina nebula complex and Gum 31 -- I. The Carina nebula complex

Author

Fujita, Shinji, Sano, Hidetoshi, Enokiya, Rei, Hayashi, Katsuhiro, Kohno, Mikito, Tsuge, Kisetsu, Tachihara, Kengo, Nishimura, Atsushi, Ohama, Akio, Yamane, Yumiko, Ohno, Takahiro, Yamada, Rin, and Fukui, Yasuo

Subjects
Astrophysics - Astrophysics of Galaxies
Abstract

Herein, we present results from observations of the 12CO (J=1-0), 13CO (J=1-0), and 12CO (J=2-1) emission lines toward the Carina nebula complex (CNC) obtained with the Mopra and NANTEN2 telescopes. We focused on massive-star-forming regions associated with the CNC including the three star clusters Tr14, Tr15, and Tr16, and the isolated WR-star HD92740. We found that the molecular clouds in the CNC are separated into mainly four clouds at velocities -27, -20, -14, and -8 km/s. Their masses are 0.7x10^4Msun, 5.0x10^4 Msun, 1.6x10^4 Msun, and 0.7x10^4 Msun, respectively. Most are likely associated with the star clusters, because of their high 12CO (J=2-1)/12CO (J=1-0) intensity ratios and their correspondence to the Spitzer 8 micron distributions. In addition, these clouds show the observational signatures of cloud--cloud collisions. In particular, there is a V-shaped structure in the position--velocity diagram and a complementary spatial distribution between the -20 km/s cloud and the -14 km/s cloud. Based on these observational signatures, we propose a scenario wherein the formation of massive stars in the clusters was triggered by a collision between the two clouds. By using the path length of the collision and the assumed velocity separation, we estimate the timescale of the collision to be ~1 Myr. This is comparable to the ages of the clusters estimated in previous studies.

Published
2020
Full Text
View/download PDF

40. FOREST Unbiased Galactic plane Imaging survey with the Nobeyama 45 m telescope (FUGIN). VI. Dense gas and mini-starbursts in the W43 giant molecular cloud complex

Author

Kohno, Mikito, Tachihara, Kengo, Torii, Kazufumi, Fujita, Shinji, Nishimura, Atsushi, Kuno, Nario, Umemoto, Tomofumi, Minamidani, Tetsuhiro, Matsuo, Mitsuhiro, Kiridoshi, Ryosuke, Tokuda, Kazuki, Hanaoka, Misaki, Tsuda, Yuya, Kuriki, Mika, Ohama, Akio, Sano, Hidetoshi, Hasegawa, Tetsuo, Sofue, Yoshiaki, Habe, Asao, Onishi, Toshikazu, and Fukui, Yasuo

Subjects
Astrophysics - Astrophysics of Galaxies
Abstract

We performed new large-scale $^{12}$CO, $^{13}$CO, and C$^{18}$O $J=$1--0 observations of the W43 giant molecular cloud complex in the tangential direction of the Scutum arm ($l\sim {30^\circ}$) as a part of the FUGIN project. The low-density gas traced by $^{12}$CO is distributed over 150 pc $\times$ 100 pc ($l \times b$), and has a large velocity dispersion (20-30 km s$^{-1}$). However, the dense gas traced by C$^{18}$O is localized in the W43 Main, G30.5, and W43 South (G29.96-0.02) high-mass star-forming regions in the W43 GMC complex, which have clumpy structures. We found at least two clouds with a velocity difference of $\sim$ 10-20 km s$^{-1}$, both of which are likely to be physically associated with these high-mass star-forming regions based on the results of high $^{13}$CO $J=$ 3-2 to $J =$ 1-0 intensity ratio and morphological correspondence with the infrared dust emission. The velocity separation of these clouds in W43 Main, G30.5, and W43 South is too large for each cloud to be gravitationally bound. We also revealed that the dense gas in the W43 GMC has a high local column density, while "the current SFE" of entire the GMC is low ($\sim 4\%$) compared with the W51 and M17 GMC. We argue that the supersonic cloud-cloud collision hypothesis can explain the origin of the local mini-starbursts and dense gas formation in the W43 GMC complex., Comment: 51 pages, 34 figures, 6 tables, accepted for publication in PASJ

Published
2020
Full Text
View/download PDF

41. High-mass star formation in Orion B triggered by cloud-cloud collision: Merging molecular clouds in NGC 2024

Author

Enokiya, Rei, Ohama, Akio, Yamada, Rin, Sano, Hidetoshi, Fujita, Shinji, Hayashi, Katsuhiro, Tsutsumi, Daichi, Torii, Kazufumi, Nishimura, Atsushi, konishi, Ryotaro, Yamamoto, Hiroaki, Tachihara, Kengo, Hasagawa, Yutaka, Kimura, Kimihiro, Ogawa, Hideo, and Fukui, Yasuo

Subjects
Astrophysics - Astrophysics of Galaxies
Abstract

We performed new comprehensive $^{13}$CO($J$=2--1) observations toward NGC 2024, the most active star forming region in Orion B, with an angular resolution of $\sim$100'' obtained with NANTEN2. We found that the associated cloud consists of two independent velocity components. The components are physically connected to the H{\sc ii} region as evidenced by their close correlation with the dark lanes and the emission nebulosity. The two components show complementary distribution with a displacement of $\sim$0.6 pc. Such complementary distribution is typical to colliding clouds discovered in regions of high-mass star formation. We hypothesize that a cloud-cloud collision between the two components triggered the formation of the late O-type stars and early B stars localized within 0.3 pc of the cloud peak. The duration time of the collision is estimated to be 0.3 million years from a ratio of the displacement and the relative velocity $\sim$3 km s$^{-1}$ corrected for probable projection. The high column density of the colliding cloud $\sim$10$^{23}$ cm$^{-2}$ is similar to those in the other high-mass star clusters in RCW 38, Westerlund 2, NGC 3603, and M42, which are likely formed under trigger by cloud-cloud collision. The present results provide an additional piece of evidence favorable to high-mass star formation by a major cloud-cloud collision in Orion., Comment: 17 pages, 13 figures, accepted for PASJ. arXiv admin note: substantial text overlap with arXiv:1706.05652

Published
2019
Full Text
View/download PDF

42. New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study

Author

Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Kazuya Kariyama, Joji Tani, Masashi Hirooka, Koichi Takaguchi, Masanori Atsukawa, Shinya Fukunishi, Ei Itobayashi, Kunihiko Tsuji, Kazuto Tajiri, Hironori Ochi, Toru Ishikawa, Satoshi Yasuda, Chikara Ogawa, Hidenori Toyoda, Takeshi Hatanaka, Takashi Nishimura, Satoru Kakizaki, Kazuhito Kawata, Noritomo Shimada, Fujimasa Tada, Kazuhiro Nouso, Akemi Tsutsui, Hideko Ohama, Asahiro Morishita, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Hisashi Kosaka, Michitaka Imai, Atsushi Naganuma, Shinichiro Nakamura, Yohei Koizumi, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, and the Real‐life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group

Subjects
atezolizumab plus bevacizumab, Glasgow prognostic score, hepatocellular carcinoma, neo‐Glasgow prognostic score, survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Aim Recently, the neo‐Glasgow prognostic score (GPS), a composite biomarker determined by the C‐reactive protein level and albumin–bilirubin grade, was developed to predict outcomes in hepatocellular carcinoma (HCC) patients who undergo hepatic resection. The present research investigated whether the neo‐GPS could predict prognosis in HCC patients treated with atezolizumab plus bevacizumab (Atez/Bev). Methods A total of 421 patients with HCC who were treated with Atez/Bev were investigated. Results Multivariate Cox hazards analysis showed that a GPS of 1 (hazard ratio (HR), 1.711; 95% confidence interval (CI), 1.106–2.646) and a GPS of 2 (HR, 4.643; 95% CI, 2.778–7.762) were independently associated with overall survival. Conversely, multivariate Cox hazards analysis showed that a neo‐GPS of 1 (HR, 3.038; 95% CI, 1.715–5.383) and a neo‐GPS of 2 (HR, 5.312; 95% CI, 2.853–9.890) were also independently associated with overall survival in this cohort. Additionally, cumulative overall survival rates differed significantly by GPS and neo‐GPS (p

Published
2023
Full Text
View/download PDF

43. Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study

Author

Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Takashi Kumada, and the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

Subjects
etiology, immune checkpoint inhibitor, non‐alcoholic steatohepatitis, propensity score matching, real‐world data, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Aim This study compared the efficacy and safety of atezolizumab and bevacizumab (Atez/Bev) in patients with viral and non‐viral infection in clinical settings. Methods We conducted the retrospective cohort study of 323 BCLC stage B or C hepatocellular carcinoma (HCC) patients with Child‐Pugh class A, and a performance status of 0 or 1 who started Atez/Bev from September 2020 to December 2021 at 22 institutions in Japan. Patients with viral infection was defined as those who were either serum anti‐HCV‐ Ab or HBs‐Ag‐positive, while patients with non‐viral infection was defined as those who were both serum anti‐HCV Ab‐ and HBs‐Ag‐negative. We constructed a propensity‐score‐matched cohort to minimize the risk of observable potential confounders. Results Propensity score matching produced 126 matched pairs for patients with viral versus non‐viral infection. After matching, the significant differences in baseline demographic features did not exist between the two groups. The objective response rate was 20.6% and 24.6% in viral‐ and non‐viral‐related HCC patients, respectively, without a significant difference (p = 0.55). The disease control rate was not also significantly different (68.3% vs 69.0%, p = 1.00). The median progression‐free survival was 7.0 months (95% confidence interval [CI] 6.0–9.6) and 6.2 months (95% CI 5.1–7.8) in patients with viral and non‐viral infection, and the 12‐month survival rates were 65.5% (95% CI 50.8–76.8) and 71.7% (95% CI 57.3–81.9) in those with viral and non‐viral infection, respectively, which were not significantly different (p = 0.33, p = 0.38). No significant difference in treatment‐related adverse events was found between the two groups. Conclusions Our etiology‐based study demonstrated that Atez/Bev showed good efficacy and safety for HCC patient with non‐viral infection as well as those with viral infection.

Published
2023
Full Text
View/download PDF

44. The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis

Author

Takeshi Hatanaka, Atsushi Naganuma, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Satoru Kakizaki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Takashi Kumada, and the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

Subjects
aspartate transaminase‐to‐alanine transaminase ratio, atezolizumab and bevacizumab, HCC‐GRIm score, hepatocellular carcinoma, lactate dehydrogenase, neutrophil‐to‐lymphocyte ratio, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Aim This study investigated whether or not the hepatocellular carcinoma modified Gustave Roussy Immune Score (HCC‐GRIm‐Score) serves as a prognostic indicator for HCC patients treated with atezolizumab and bevacizumab (Atez/Bev). Methods A total of 405 HCC patients who received Atez/Bev from September 2020 to January 2022 at 22 different institutions were included in this retrospective study. The HCC‐GRIm score was based on the combination of the albumin level (

Published
2023
Full Text
View/download PDF

45. Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib

Author

Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hiroshi Shibata, Tomoko Aoki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, and Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

Subjects
atezolizumab plus bevacizumab, hepatocellular carcinoma, lenvatinib, prognosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background/Aim A comparison of therapeutic efficacy between atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib treatment given as first‐line therapy for unresectable hepatocellular carcinoma (u‐HCC) in regard to progression‐free survival (PFS) overall survival (OS) has not been reported. We aimed to elucidate which of those given as initial treatment for u‐HCC has greater prognostic impact on PFS and OS of affected patients, retrospectively. Materials/Methods From 2020 to January 2022, 251 u‐HCC (Child–Pugh A, ECOG PS 0/1, BCLC‐B/C) treated were enrolled (Atez/Bev‐group, n = 194; lenvatinib‐group, n = 57). PFS and OS were analyzed following adjustment based on inverse probability weighting (IPW). Results There was a greater number of patients with macro‐vascular invasion in Atez/Bev‐group (22.7% vs. 8.8%, p = 0.022). In lenvatinib‐group, the frequencies of appetite loss (38.6% vs. 19.6%, p = 0.002), hypothyroidism (21.1% vs. 6.7%, p = 0.004), hand foot skin reaction (19.3% vs. 1.0%, p

Published
2023
Full Text
View/download PDF

46. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Niizeki, Takashi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Stefanini, Bernardo, Hiraoka, Atsushi, Sho, Takuya, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Campani, Claudia, Amadeo, Elisabeth, Rossari, Federico, Burgio, Valentina, Cascinu, Stefano, Scartozzi, Mario, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

48. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study

Author

Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Shimada, Noritomo, Kawata, Kazuhito, Kosaka, Hisashi, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, and Kumada, Takashi

Published
2022
Full Text
View/download PDF

49. Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab

Author

Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Shimada, Noritomo, Kawata, Kazuhito, Kosaka, Hisashi, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, and Kumada, Takashi

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results